Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone201-329-7300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$828 million
Profitability
Miscellaneous
Employees1,600
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Phibro Animal Health (NASDAQ:PAHC) Frequently Asked Questions
What is Phibro Animal Health's stock symbol?
Phibro Animal Health trades on the NASDAQ under the ticker symbol "PAHC."
How often does Phibro Animal Health pay dividends? What is the dividend yield for Phibro Animal Health?
Phibro Animal Health announced a quarterly dividend on Monday, July 29th. Investors of record on Wednesday, September 4th will be paid a dividend of $0.12 per share on Wednesday, September 25th. This represents a $0.48 annualized dividend and a yield of 2.13%. The ex-dividend date is Tuesday, September 3rd. View Phibro Animal Health's Dividend History.
How were Phibro Animal Health's earnings last quarter?
Phibro Animal Health Corp (NASDAQ:PAHC) announced its quarterly earnings results on Tuesday, August, 27th. The company reported $0.33 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.34 by $0.01. The business earned $203.90 million during the quarter, compared to the consensus estimate of $206 million. Phibro Animal Health had a net margin of 6.59% and a return on equity of 29.99%. Phibro Animal Health's revenue was down 3.7% compared to the same quarter last year. During the same period last year, the company earned $0.46 earnings per share. View Phibro Animal Health's Earnings History.
When is Phibro Animal Health's next earnings date?
What guidance has Phibro Animal Health issued on next quarter's earnings?
Phibro Animal Health issued an update on its FY20 earnings guidance on Tuesday, August, 27th. The company provided earnings per share guidance of $1.08 -1.15 for the period, compared to the Thomson Reuters consensus estimate of $1.66. The company issued revenue guidance of $833 -863 million, compared to the consensus revenue estimate of $857.96 million.
What price target have analysts set for PAHC?
5 analysts have issued 12 month price objectives for Phibro Animal Health's stock. Their predictions range from $18.00 to $42.00. On average, they expect Phibro Animal Health's stock price to reach $26.60 in the next year. This suggests a possible upside of 18.1% from the stock's current price. View Analyst Price Targets for Phibro Animal Health.
What is the consensus analysts' recommendation for Phibro Animal Health?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phibro Animal Health in the last year. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Phibro Animal Health.
Has Phibro Animal Health been receiving favorable news coverage?
Media coverage about PAHC stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Phibro Animal Health earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Phibro Animal Health.
Are investors shorting Phibro Animal Health?
Phibro Animal Health saw a decline in short interest in September. As of September 30th, there was short interest totalling 623,400 shares, a decline of 5.9% from the August 30th total of 662,400 shares. Based on an average daily volume of 225,000 shares, the days-to-cover ratio is currently 2.8 days. Currently, 3.1% of the shares of the company are short sold. View Phibro Animal Health's Current Options Chain.
Who are some of Phibro Animal Health's key competitors?
Some companies that are related to Phibro Animal Health include FibroGen (FGEN), Evotec (EVTCY), Allakos (ALLK), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Genmab A/S (GMAB), Emergent Biosolutions (EBS), HUTCHISON CHINA/S (HCM), Myokardia (MYOK), Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE) and Biohaven Pharmaceutical (BHVN).
What other stocks do shareholders of Phibro Animal Health own?
Who are Phibro Animal Health's key executives?
Phibro Animal Health's management team includes the folowing people:
- Mr. Jack Clifford Bendheim, Chairman, Pres & CEO (Age 72)
- Mr. Larry L. Miller, Chief Operating Officer (Age 55)
- Mr. Dean J. Warras, Pres of Animal Health & Nutrition - North America (Age 50)
- Mr. Richard G. Johnson, Chief Financial Officer (Age 70)
- Mr. Thomas G. Dagger, Sr. VP, Gen. Counsel & Corp. Sec. (Age 61)
Who are Phibro Animal Health's major shareholders?
Phibro Animal Health's stock is owned by a number of of institutional and retail investors. Top institutional investors include Confluence Investment Management LLC (0.36%), Rhumbline Advisers (0.16%), Bridge City Capital LLC (0.13%), Nisa Investment Advisors LLC (0.05%), State of Alaska Department of Revenue (0.04%) and Meeder Asset Management Inc. (0.03%). Company insiders that own Phibro Animal Health stock include Bfi Co, Llc, Daniel M Bendheim, Dean J Warras, E Thomas Corcoran, Jack Bendheim and Larry Lee Miller. View Institutional Ownership Trends for Phibro Animal Health.
Which major investors are buying Phibro Animal Health stock?
PAHC stock was bought by a variety of institutional investors in the last quarter, including Bridge City Capital LLC, Nisa Investment Advisors LLC, State of Alaska Department of Revenue, Meeder Asset Management Inc., Confluence Investment Management LLC, Rhumbline Advisers and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Phibro Animal Health.
How do I buy shares of Phibro Animal Health?
Shares of PAHC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Phibro Animal Health's stock price today?
One share of PAHC stock can currently be purchased for approximately $22.52.
How big of a company is Phibro Animal Health?
Phibro Animal Health has a market capitalization of $911.00 million and generates $828 million in revenue each year. The company earns $54.71 million in net income (profit) each year or $1.53 on an earnings per share basis. Phibro Animal Health employs 1,600 workers across the globe.View Additional Information About Phibro Animal Health.
What is Phibro Animal Health's official website?
How can I contact Phibro Animal Health?
Phibro Animal Health's mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company can be reached via phone at 201-329-7300 or via email at [email protected]
MarketBeat Community Rating for Phibro Animal Health (NASDAQ PAHC)
MarketBeat's community ratings are surveys of what our community members think about Phibro Animal Health and other stocks. Vote "Outperform" if you believe PAHC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAHC will underperform the S&P 500 over the long term. You may vote once every thirty days.
